Jonathan Chou, MD, PhD
Assistant Professor
Medicine
School of Medicine

Our current research projects include developing novel CAR T and radioimmunotherapies for prostate and bladder cancers (including identifying new therapeutic targets using transcriptomic and proteomic approaches), and understanding resistance mechanisms to antibody-drug conjugates and other surface-protein targeting modalities. In addition, we are interested in the role of CDK12 in regulating transcription and replication, and identifying new therapeutic approaches to treat this aggressive subtype of disease. I completed my postdoctoral research fellowship with Drs. Felix Feng and Alan Ashworth and my clinical training with Drs. Eric Small, Terence Friedlander and Chuck Ryan. I completed my PhD dissertation in the Biomedical Sciences program at UCSF with the late Dr. Zena Werb, and studied transcriptional regulation of metastasis and the tumor microenvironment.

• CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
  bioRxiv : the preprint server for biology 2024 Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, …
• Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024 Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA
• Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
  Theranostics 2024 Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR
• Large tandem duplications in cancer result from transcription and DNA replication collisions.
  medRxiv : the preprint server for health sciences 2024 Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L
• Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
  Clinical genitourinary cancer 2023 Shipp C, Jindal T, Chou J, Friedlander TW, Koshkin VS, Kumar V
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…
• The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
  Cancer research 2023 Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, …
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, Ali U, Meher N, Wadhwa A, Dhrona S, Dasari C, Beckford-Vera D, Su Y, Tang R, Zhang L, He J, Wilson DM, Aggarwal R, VanBrocklin …
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ
• Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
  Urologic oncology 2022 Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ
• Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.
  Cancer research 2022 O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A
• The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
  Cancer research 2022 Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, …
• CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, …
• APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
  Frontiers in oncology 2022 Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J,…
• TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
  European urology oncology 2022 Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
• Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.
  Clinical genitourinary cancer 2021 Jindal T, Chou J, Friedlander T, Barata PC, Koshkin VS
• Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
  Cancer 2021 Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, …
• An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
  Nature communications 2021 Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
  European urology 2021 Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, …
• Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
  Cancer 2021 Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS
• Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo…
• Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P
• Autoantibody Landscape in Patients with Advanced Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M…
• The DNA methylation landscape of advanced prostate cancer.
  Nature genetics 2020 Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, …
• MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy.
  Life science alliance 2019 Owyong M, Chou J, van den Bijgaart RJ, Kong N, Efe G, Maynard C, Talmi-Frank D, Solomonov I, Koopman C, Hadler-Olsen E, Headley M, Lin C, Wang CY, Sagi I, Werb Z, Plaks V
• DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley …
• Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, …
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
  Cell 2018 Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A, PCF/SU2C International …
• Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.
  Annals of translational medicine 2018 Kornberg Z, Chou J, Feng FY, Ryan CJ
• HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice.
  Proceedings of the National Academy of Sciences of the United States of America 2018 Devignes CS, Aslan Y, Brenot A, Devillers A, Schepers K, Fabre S, Chou J, Casbon AJ, Werb Z, Provot S
• GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.
  Oncogene 2017 Shahi P, Wang CY, Chou J, Hagerling C, Gonzalez Velozo H, Ruderisch A, Yu Y, Lai MD, Werb Z
• Respiratory Failure in a Woman 8 Months After an Allogeneic Stem Cell Transplant.
  JAMA oncology 2016 Chou J, Wallender E, Schwartz BS
• Electrocardiography Evolution in a Woman Presenting With Alcohol Withdrawal Seizures and Cocaine Use.
  JAMA internal medicine 2016 Chou J, Beutler LR, Goldschlager N
• Metalloproteinases: a Functional Pathway for Myeloid Cells.
  Microbiology spectrum 2016 Chou J, Chan MF, Werb Z
• The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion.
  The Journal of biological chemistry 2014 Shahi P, Slorach EM, Wang CY, Chou J, Lu A, Ruderisch A, Werb Z
• microRNA-mediated regulation of the tumor microenvironment.
  Cell cycle (Georgetown, Tex.) 2013 Chou J, Shahi P, Werb Z
• MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment.
  Cancer discovery 2012 Chou J, Werb Z
• The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
  Cancer discovery 2012 Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, …
• GATA3 in development and cancer differentiation: cells GATA have it!
  Journal of cellular physiology 2010 Chou J, Provot S, Werb Z
• Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival.
  Nature 2005 Allen E, Ding J, Wang W, Pramanik S, Chou J, Yau V, Yang Y